Protein Kinase C inhibitor Molecule Effect Partial Reversal of Spliceopathy in Myotonic Dystrophy Type 2 Cell Line Journal of Natural Sciences Research, Vol.11, No.14

Article Sidebar

PDF

     Abstract Views | PDF Downloads:
0 / 0

Published: 2020-08-22
DOI: https://doi.org/10.60951/afrischolar-545
Keywords:
therapeutics, spliceopathy, Protein Kinase C inhibitor, Myotonic dystrophy

Main Article Content

Inyang U. Udosen
Department of Genetics & Biotechnology, Akwa Ibom State University, Nigeria

Abstract

Myotonic dystrophy is a neuromuscular disease which manifest as two forms namely type 1 (DM1) and type 2 (DM2). One of the major molecular events associated with the disease condition is misregulation of splicing resulting in spliceopathy. This study was performed to assess the effect of protein kinase C (PKC) inhibitors- Ro 31-8220 and hypericin- on the splicing of insulin receptor (IR) and muscleblind-like (MBNL1) in myotonic dystrophy type 2 (DM2) cell line. The results of this study demonstrated that only Ro 31-8820 was able to effect partial rescue of missplicing of insulin receptor and muscleblind-like 1. It indicates that it could be a possible therapeutic agent for treatment of DM2.

Downloads

Download data is not yet available.

Article Details

Issue

Repository (Set 10)

Section

Publications
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

All materials deposited in the Afrischolar Discovery Repository are made openly available under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), unless otherwise indicated.

Under this license, users are free to:

  • Share — copy and redistribute the material in any medium or format
  • Adapt — remix, transform, and build upon the material for any purpose, including commercial use

These freedoms are granted provided that appropriate credit is given to the original author(s), a link to the license is included, and any changes made are clearly indicated. Attribution must not suggest endorsement by the author(s) or the repository.

Authors retain full copyright of their work while granting Afrischolar Discovery Repository a non-exclusive license to store, preserve, and disseminate the content for academic and public use.

Users must not apply legal terms or technological measures that legally restrict others from exercising the rights permitted by the license.

Where third-party content is included, users are responsible for ensuring compliance with the applicable licensing terms for such materials.

By submitting content to the Afrischolar Discovery Repository, contributors affirm that they have the right to distribute their work under the CC BY 4.0 license.

For full license details, visit: https://creativecommons.org/licenses/by/4.0/

How to Cite

Udosen, I. (2020). Protein Kinase C inhibitor Molecule Effect Partial Reversal of Spliceopathy in Myotonic Dystrophy Type 2 Cell Line: Journal of Natural Sciences Research, Vol.11, No.14. Afrischolar Discovery Repository (Annex), 17-22. https://doi.org/10.60951/afrischolar-545

References

1. Harper, P. S. (2001) Myotonic Dystrophy 3rd edition. W. B. Saunders. London.

2. Machuca-Tzili, L., Brook, D. & Hilton-Jones, D. (2005) Clinical and molecular aspects of the myotonic dystrophies: a review. Muscle Nerve, 32, 1-18.

3. Liquori, C. L., Ricker, K., Moseley, M. L., Jacobsen, J. F., Kress, W., Naylor, S. L., Day, J. W. & Ranum, L. P. (2001) Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9. Science, 293, 864-7.

4. Fardaei, M., Larkin, K., Brook, J. D. & Hamshere, M. G. (2001) In vivo co-localisation of MBNL protein with DMPK expanded-repeat transcripts. Nucleic Acids Res, 29, 2766-71.

5. Fardaei, M., Rogers, M. T., Thorpe, H. M., Larkin, K., Hamshere, M. G., Harper, P. S. & Brook, J. D. (2002) Three proteins, MBNL, MBLL and MBXL, co-localize in vivo with nuclear foci of expanded-repeat transcripts in DM1 and DM2 cells. Hum Mol Genet, 11, 805-14.

6. Miller, J. W., Urbinati, C. R., Teng-Umnuay, P., Stenberg, M. G., Byrne, B. J., Thornton, C. A. & Swanson, M. S. (2000) Recruitment of human muscleblind proteins to (CUG)(n) expansions associated with myotonic dystrophy. EMBO J, 19, 4439-48.

7. Mankodi, A., Urbinati, C. R., Yuan, Q. P., Moxley, R. T., Sansone, V., Krym, M., Henderson, D., Schalling, M., Swanson, M. S. & Thornton, C. A. (2001) Muscleblind localizes to nuclear foci of aberrant RNA in myotonic dystrophy types 1 and 2. Hum Mol Genet, 10, 2165-70.

8. Arambula, J. F., Ramisetty, S. R., Baranger, A. M. & Zimmerman, S. C. (2009) A simple ligand that selectively targets CUG trinucleotide repeats and inhibits MBNL protein binding. Proc Natl Acad Sci U S A, 106, 16068-73.

9. Gareiss, P. C., Sobczak, K., McNaughton, B. R., Palde, P. B., Thornton, C. A. & Miller, B. L. (2008) Dynamic combinatorial selection of molecules capable of inhibiting the (CUG) repeat RNA-MBNL1 interaction in vitro: discovery of lead compounds targeting myotonic dystrophy (DM1). J Am Chem Soc, 130, 16254-61.

10. Pushechnikov, A., Lee, M. M., Childs-Disney, J. L., Sobczak, K., French, J. M., Thornton, C. A. & Disney, M. D. (2009) Rational design of ligands targeting triplet repeating transcripts that cause RNA dominant disease: application to myotonic muscular dystrophy type 1 and spinocerebellar ataxia type 3. J Am Chem Soc, 131, 9767-79.

11. Warf, M. B., Nakamori, M., Matthys, C. M., Thornton, C. A. & Berglund, J. A. (2009) Pentamidine reverses the splicing defects associated with myotonic dystrophy. Proc Natl Acad Sci U S A, 106, 18551-6.

12. Ranum, L. P. & Cooper, T. A. (2006) RNA-mediated neuromuscular disorders. Annu Rev Neurosci, 29, 259-77.

13. Savkur, R. S., Philips, A. V. & Cooper, T. A. (2001) Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy. Nat Genet, 29, 40-7.

14. Savkur, R. S., Philips, A. V., Cooper, T. A., Dalton, J. C., Moseley, M. L., Ranum, L. P. & Day, J. W. (2004) Insulin receptor splicing alteration in myotonic dystrophy type 2. Am J Hum Genet, 74, 1309-13.

15. Machuca-Tzili, L., Thorpe, H., Robinson, T. E., Sewry, C. & Brook, J. D. (2006) Flies deficient in Muscleblind protein model features of myotonic dystrophy with altered splice forms of Z-band associated transcripts. Hum Genet, 120, 487-99.

16. Lin, X., Miller, J. W., Mankodi, A., Kanadia, R. N., Yuan, Y., Moxley, R. T., Swanson, M. S. & Thornton, C. A. (2006) Failure of MBNL1-dependent post-natal splicing transitions in myotonic dystrophy. Hum Mol Genet, 15, 2087-97.

17. Nakamori, M., Kimura, T., Fujimura, H., Takahashi, M. P. & Sakoda, S. (2007) Altered mRNA splicing of dystrophin in type 1 myotonic dystrophy. Muscle Nerve, 36, 251-7.

18. Philips, A. V., Timchenko, L. T. & Cooper, T. A. (1998) Disruption of splicing regulated by a CUG-binding protein in myotonic dystrophy. Science, 280, 737-41.

19. Sergeant, N., Sablonniere, B., Schraen-Maschke, S., Ghestem, A., Maurage, C. A., Wattez, A., Vermersch, P. & Delacourte, A. (2001) Dysregulation of human brain microtubule-associated tau mRNA maturation in myotonic dystrophy type 1. Hum Mol Genet, 10, 2143-55.

20. Buj-Bello, A., Furling, D., Tronchere, H., Laporte, J., Lerouge, T., Butler-Browne, G. S. & Mandel, J. L. (2002) Muscle-specific alternative splicing of myotubularin-related 1 gene is impaired in DM1 muscle cells. Hum Mol Genet, 11, 2297-307.

21. Kanadia, R. N., Johnstone, K. A., Mankodi, A., Lungu, C., Thornton, C. A., Esson, D., Timmers, A. M., Hauswirth, W. W. & Swanson, M. S. (2003) A muscleblind knockout model for myotonic dystrophy. Science, 302, 1978-80.

22. Kimura, T., Nakamori, M., Lueck, J. D., Pouliquin, P., Aoike, F., Fujimura, H., Dirksen, R. T., Takahashi, M. P., DulhuntyULHUNTY, A. F. & SAKODA, S. (2005) Altered mRNA splicing of the skeletal muscle ryanodine receptor and sarcoplasmic/endoplasmic reticulum Ca2+-ATPase in myotonic dystrophy type 1. Hum Mol Genet, 14, 2189-200.

23. Ketley, A., Chen, C. Z., Li, X., Arya, S., Robinson, T. E., Granados-Riveron, J., Udosen, I., Morris, G. E., Holt, I., Furling, D., Chaouch, S., Haworth, B., Southall, N., Shinn, P., Zheng, W., Austin, C. P., Hayes, C. J. & Brook, D.(2013) High-content screening identifies small molecules that remove nuclear foci, affect MBNL distribution and CELF1 protein levels via a PKC-independent pathway in myotonic dystrophy cell lines. Human Molecular Genetics 1-12.

24. Wojciechowska, M., Sobczak, K., Kozlowski, P., Sedehizadeh1, S., Wojtkowiak-Szlachcic, A., Czubak, K., Markus, R., Lusakowska, A., Kaminska, A., & Brook, J. D. (2018) Quantitative Methods to Monitor RNA Biomarkers in Myotonic Dystrophy. Scientific Reports, 8, 1-13.

25. Botta, A., Rinaldi, F., Catalli, C., Vergani, L., Bonifazi, E., Romeo, V., Loro, E., Viola, A., Angelini, C. & Novelli, G. (2008) The CTG repeat expansion size correlates with the splicing defects observed in muscles from myotonic dystrophy type 1 patients. J Med Genet, 45, 639-46.

26. Cardani, R., Baldassa, S., Botta, A., Rinaldi, F., Novelli, G., Mancinelli, E & Meola, G. (2009) Ribonuclear inclusions and MBNL1 nuclear sequestration do not affect myoblast differentiation but alter gene splicing in myotonic dystrophy type 2. Neuromuscul Disord, 19, 335-43.

27. Dansithong, W., Paul, S., Comai, L. & Reddy, S. (2005) MBNL1 is the primary determinant of focus formation and aberrant insulin receptor splicing in DM1. J Biol Chem, 280, 5773-80.

28. Ho, T. H., Charlet, B. N., Poulos, M. G., Singh, G., Swanson, M. S. & Cooper, T. A. (2004) Muscleblind proteins regulate alternative splicing. EMBO J, 23, 3103-12.

29. Paul, S., Dansithong, W., Kim, D., Rossi, J., Webster, N. J., Comai, L. & Reddy, S. (2006) Interaction of muscleblind, CUG-BP1 and hnRNP H proteins in DM1-associated aberrant IR splicing. EMBO J, 25, 4271- 83.

30. Wang, G. S., Kuyumcu-Martinez, M. N., Sarma, S., Mathur, N., Wehrens, X. H. & Cooper, T. A. (2009) PKC inhibition ameliorates the cardiac phenotype in a mouse model of myotonic dystrophy type 1. J Clin Invest, 119, 3797-806.